Drugs / IMAGABALIN
IMAGABALIN
also known as
PD-0332334 · Imagabalin hcl · IMAGABALIN HYDROCHLORIDE · Imagabalina · Imagabaline · PD 0332334-0002 · PD 0332334-0002 (PF00195889-01) · PF-00195889 · +1 more
Trials 14
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 16 trials | ||||||
| Phase 1 | NCT00820794 | May → Jun 2009 | generalized anxiety disorder | Pfizer | Withdrawn | No outcome recorded |
| Phase 1 | NCT00809536 | Jan → Feb 2009 | generalized anxiety disorder | Pfizer | Terminated | No outcome recorded |
| Phase 1 | NCT00800280 | Jan → Feb 2009 | generalized anxiety disorder | Pfizer | Terminated | No outcome recorded |
| Phase 1 | NCT00730145 | Sep 2008 → Jan 2009 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT00721422 | Aug 2008 → Feb 2009 | impaired renal function disease | Pfizer | Terminated | No outcome recorded |
| Phase 1 | NCT00537615 | Sep → Oct 2007 | generalized anxiety disorder | Pfizer | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00921063 | Nov 2005 → Jul 2006 | generalized anxiety disorder | Pfizer | Completed | No outcome recorded |
| Phase 37 trials | ||||||
| Phase 3 | NCT00738738 | Jan → Feb 2009 | generalized anxiety disorder | Pfizer | Withdrawn | No outcome recorded |
| Phase 3 | NCT00735267 | Oct 2008 → Apr 2009 | generalized anxiety disorder | Pfizer | Terminated | No outcome recorded |
| Phase 3 | NCT00836069 | Oct 2008 → Feb 2009 | anxiety disorder | Cedars-Sinai Medical Center | Terminated | No outcome recorded |
| Phase 3 | NCT00658762 | May 2008 → Apr 2009 | generalized anxiety disorder | Pfizer | Terminated | No outcome recorded |
| Phase 3 | NCT00658372 | May 2008 → Mar 2009 | generalized anxiety disorder | Pfizer | Terminated | No outcome recorded |
| Phase 3 | NCT00658008 | Apr 2008 → Mar 2009 | generalized anxiety disorder | Pfizer | Terminated | No outcome recorded |
| Phase 3 | NCT00542685 | Oct 2007 → Dec 2008 | generalized anxiety disorder | Pfizer | Completed | No outcome recorded |
Evidence & citations 12 cited values
Every value below carries the sentence it was read from. 15 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IMAGABALIN | ChEMBL registry synonym — accepted as the source's own label CHEMBL2103836 ↗ |
| Known as | Imagabalin hcl | ChEMBL registry synonym — accepted as the source's own label CHEMBL2103836 ↗ |
| Known as | IMAGABALIN HYDROCHLORIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL2103836 ↗ |
| Known as | Imagabalina | ChEMBL registry synonym — accepted as the source's own label CHEMBL2103836 ↗ |
| Known as | Imagabaline | ChEMBL registry synonym — accepted as the source's own label CHEMBL2103836 ↗ |
| Known as | PD 0332334-0002 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2103836 ↗ |
| Known as | PD 0332334-0002 (PF00195889-01) | ChEMBL registry synonym — accepted as the source's own label CHEMBL2103836 ↗ |
| Known as | PD-0332334 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00730145 ↗ |
| Known as | PF-00195889 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2103836 ↗ |
| Known as | PF-00195889-01 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2103836 ↗ |
| Modality | Other / unclassified | “PD 0332334-α2δ ligand” NCT00836069 ↗ |
| Route | Oral | “Capsules, oral, 300 mg BID, 8 weeks with 2 week taper.” NCT00542685 ↗ |